These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 11147229

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ.
    Cancer; 2004 Dec 15; 101(12):2788-801. PubMed ID: 15481055
    [Abstract] [Full Text] [Related]

  • 3. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ.
    J Clin Oncol; 2000 Feb 15; 18(3):547-61. PubMed ID: 10653870
    [Abstract] [Full Text] [Related]

  • 4. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
    O'Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H.
    Cancer; 2008 Oct 15; 113(8):2097-101. PubMed ID: 18720356
    [Abstract] [Full Text] [Related]

  • 5. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM.
    Cancer; 2004 Mar 15; 100(6):1179-85. PubMed ID: 15022284
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F, Balabanov S, Soldini D, Samaras P, Gerber B, Manz MG, Goede JS.
    Ann Hematol; 2018 Feb 15; 97(2):277-287. PubMed ID: 29147847
    [Abstract] [Full Text] [Related]

  • 8. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.
    Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM.
    Blood; 1995 Sep 15; 86(6):2091-7. PubMed ID: 7662956
    [Abstract] [Full Text] [Related]

  • 9. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
    Weiser MA, O'Brien S, Thomas DA, Pierce SA, Lam TP, Kantarjian HM.
    Cancer; 2002 Jan 15; 94(2):285-91. PubMed ID: 11900213
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
    Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM.
    J Clin Oncol; 2010 Aug 20; 28(24):3880-9. PubMed ID: 20660823
    [Abstract] [Full Text] [Related]

  • 13. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
    Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H.
    J Clin Oncol; 1999 Aug 20; 17(8):2461-70. PubMed ID: 10561310
    [Abstract] [Full Text] [Related]

  • 14. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
    Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H.
    Cancer; 2010 Oct 01; 116(19):4580-9. PubMed ID: 20572037
    [Abstract] [Full Text] [Related]

  • 15. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
    Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H.
    JAMA Oncol; 2018 Feb 01; 4(2):230-234. PubMed ID: 28859185
    [Abstract] [Full Text] [Related]

  • 16. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
    Fayad L, Thomas D, Romaguera J.
    Clin Lymphoma Myeloma; 2007 Dec 01; 8 Suppl 2():S57-62. PubMed ID: 18284717
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.
    Weiss M.
    Hematol Oncol Clin North Am; 2001 Feb 01; 15(1):1-7, v. PubMed ID: 11253603
    [Abstract] [Full Text] [Related]

  • 20. Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
    Rausch CR, Jabbour EJ, Kantarjian HM, Kadia TM.
    Cancer; 2020 Mar 15; 126(6):1152-1160. PubMed ID: 31794095
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.